Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

[1]  J. Lancet,et al.  CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. , 2018, Future oncology.

[2]  Karen Campbell,et al.  64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[3]  K. Strasser-Weippl,et al.  Current and emerging therapies of HER2-positive metastatic breast cancer. , 2016, Breast.

[4]  S. Alzghari,et al.  Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[5]  O. Griffith,et al.  The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment , 2016, Oncogene.

[6]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[7]  Meiyuan Xing,et al.  Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials , 2015, PloS one.

[8]  C. Desmedt,et al.  Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Maeda,et al.  Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls , 2015, Expert opinion on drug delivery.

[10]  M. Campiglio,et al.  Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. , 2014, Cancer research.

[11]  Ana C. Gregório,et al.  Bridging cancer biology and the patients' needs with nanotechnology-based approaches. , 2014, Cancer treatment reviews.

[12]  C. Hudis,et al.  Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. , 2014 .

[13]  Seiji Miura,et al.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[14]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[15]  N. Aceto,et al.  Mammary tumor formation and metastasis evoked by a HER2 splice variant. , 2013, Cancer research.

[16]  R. Kerbel,et al.  Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. , 2013, Breast.

[17]  U. Nielsen,et al.  HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. , 2012, Toxicology and applied pharmacology.

[18]  P. Sonneveld,et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. Muggia,et al.  Phase III data on Caelyx in ovarian cancer. , 2001, European journal of cancer.

[21]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[22]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[23]  M. Hung,et al.  A novel splice variant of HER2 with increased transformation activity , 1998, Molecular carcinogenesis.

[24]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Farthing,et al.  Lactobacilli to prevent traveler's diarrhea? , 1995, The New England journal of medicine.

[26]  J. Silber,et al.  Doxorubicin-induced cardiotoxicity. , 1995, The New England journal of medicine.

[27]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.